NR4A2, a member of the nuclear receptor transcription factor superfamily, modulates the immune microenvironment of glioblastoma, enhancing, CD8+ T cell antigen presentation, microglial plasticity, and the therapeutic efficacy of immune checkpoint blockade in vivo.39 This evidence concerns the gene CD8A and glioblastoma.